The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Dec. 14, 2012
Applicant:

Novartis Ag, Basel, CH;

Inventors:

Nigel Graham Cooke, Oberwil, CH;

Paulo Antonio Fernandes Gomes Dos Santos, Basel, CH;

Pascal Furet, Thann, FR;

Christina Hebach, Muenchenstein, CH;

Klemens Hoegenauer, Oberwil, CH;

Gregory Hollingworth, Kent, GB;

Christoph Kalis, Gundelfingen, DE;

Ian Lewis, Riehen, CH;

Alexander Baxter Smith, Niffer, FR;

Nicolas Soldermann, Village-Neuf, FR;

Frederic Stauffer, Hesingue, FR;

Ross Strang, Hagenthal le Bas, FR;

Frank Stowasser, Murg, DE;

Nicola Tuffilli, Moehlin, CH;

Anette Von Matt, Biel-Benken, CH;

Romain Wolf, Schlierbach, FR;

Frederic Zecri, Brookline, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/517 (2006.01); A61K 31/551 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 239/74 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); C07D 239/74 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/14 (2013.01); C07D 487/08 (2013.01);
Abstract

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.


Find Patent Forward Citations

Loading…